Characterizing and Targeting Replication Stress Response Defects in Breast Cancer.

摘要

During the fifth year of this project, we have successfully verified AXL protein as a reliable membrane marker for replication stress response defect (RSRD) breast cancer cells and we demonstrated the potential to use isotope-labeled anti-human AXL antibody to detect RSRD breast cancer cells in vivo. In addition, we have clearly demonstrated the in vivo therapeutic effects of MEK inhibitor, AZD6244, and ERK inhibitor, SCH772984 on targeting RSRD breast cancer cells in two xenograft mouse models